Developing therapies for type 1 diabetes

Diamyd® and Remygen® are drugs in clinical development phase,
aimed to preserve and restore the body's insulin production.


We diligently focus on advancing treatments that are safe, accessible and that intercept the disease early before complications begin to manifest.

Ulf Hannelius
President and CEO, Diamyd Medical AB


Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development.

We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapeutic Remygen®.

Diamyd® and Remygen® are evaluated in ongoing clinical studies. The therapies target the underlying causes of diabetes, dysfunction and loss of the pancreas's insulin-producing cells.

Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.



A small number of employees constitute Diamyd Medical's core which collaborates with a global network of clinics, researchers and production units. Regulatory expertise and analysis- and laboratory services are contracted as needed during the project phases. The model is based on long-term collaborations, internal core competence and cost efficiency.

Order GAD for preclinical research